Classification of myositis

Nature Reviews Rheumatology

Volumn 14, Issue 5, 2018, Pages 269-278

  Lundberg, Ingrid E ^a,b   De Visser, Marianne ^c   Werth, Victoria P ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL OUTCOME; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; MUSCLE BIOPSY; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; CLASSIFICATION; COMORBIDITY; IMMUNOLOGY; LUNG; PHENOTYPE; SKIN;

AUTOANTIBODIES; COMORBIDITY; HUMANS; LUNG; MYOSITIS; PHENOTYPE; SKIN;

EID: 85045884483     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2018.41     Document Type: Review

References (66)

1. Dalakas, M.& Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971-982 (2003).
2. Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337-345 (2004).
3. Euwer, R. & Sontheimer, R. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J. Am. Acad. Dermatol. 24, 959 (1991).
4. Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360-374 (1991).
5. Lundberg, I. E., Miller, F. W., Tjärnlund, A. & Bottai, M. Diagnosis and classification of idiopathic inflammatory myopathies. J. Intern. Med. 280, 39-51 (2016).
6. Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 1955-1964 (2017).
7. Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 69, 2271-2282 (2017).
8. Medsger, T. A. Jr, Dawson Jr, W. N. & Masi, A. T. The epidemiology of polymyositis. Am. J. Med. 48, 715-723 (1970).
9. DeVere, R. & Bradley, W. G. Polymyositis: its presentation, morbidity and mortality. Brain 98, 637-666 (1975).
10. Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344-347 (1975).
11. Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403-407 (1975).
12. Bohan, A. & Peter, J. B. Bowman, R. L. & Pearson, C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56, 255-286 (1977).
13. Tanimoto, K. et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 22, 668-674 (1995).
14. Targoff, I. N. et al. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9, 527-535 (1997).
15. Troyanov, Y. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84, 231-249 (2005).
16. Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J. Rheumatol. 44, 319-325 (2017).
17. Trallero-Araguás, E.et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin. Arthritis Rheum. 46, 225-231(2016).
18. Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8-23 (2016).
19. McHugh, N.J. & Tansley, S.L. Autoantibodies in myositis Nat. Rev. Rheumatol. https://doi. org/10.1038/nrrheum.2018.56 (2018).
20. Machado, P. M. et al. Ongoing developments in sporadic inclusion body myositis. Curr. Rheumatol. Rep. 16, 477 (2014).
21. Pearson, C. M. in Arthritis (and Allied Conditions) (ed. McCarty, D. J.) 742-761 (Lea & Febiger, Philadelphia, 1979).
22. Euwer, R. & Sontheimer, R. D. Amyopathic dermatomyositis: a review. J. Invest. Dermatol. 100, 124S-127S (1993)
23. Gerami, P., Schope, J. M., McDonald, L., Walling, H. W. & Sontheimer, R. D. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J. Am. Acad. Dermatol. 54, 597-613 (2006)..
24. Hsiung, S. H. et al. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. J. Am. Acad. Dermatol. 48 (Suppl. 2). S11-S14 (2003).
25. Hamaguchi, Y. et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch. Dermatol. 147, 391-398 (2011).
26. Fiorentino, D., Chung, L., Zwerner, J., Roen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype in dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25-34 (2012).
27. Muro, Y. et al. Cutaneous manifestations in dermatomyositis: key clinical and serological features - a comprehensive review. Clin. Rev. Allergy Immunol. 51, 293-302 (2016).
28. Mukae, H. et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136, 1341-1347 (2009).
29. Ang, C. C. et al. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. Br. J. Dermatol. 176, 231-233 (2017).
30. Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449-455 (2015).
31. Fiorentino, D. & Casciola-Rosen, L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 64, 346-349 (2012).
32. Rogers, A., Chung, L., Li. S., Casciola-Rosen, L. & Fiorentino, D. F. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909-1914 (2017).
33. Fujimoto, M., Watanabe, R., Ishitsuka, Y. & Okiyama, N. Recent advances in dermatomyositis-specific autoantibodies. Curr. Opin. Rheumatol. 28, 636-644 (2016).
34. Klein, R. Q. et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br. J. Dermatol. 159, 887-894 (2008).
35. Anyanwu, C. O. et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br. J. Dermatol. 173, 969-974 (2015).
36. Tiao, J. et al. Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 177, 1086-1092 (2017).
37. Tiao, J. et al. The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 176, 423-430 (2017).
38. Robinson, E. S., Feng, R., Okawa, J. & Werth, V. P. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br. J. Dermatol. 172, 169-174 (2015).
39. Yassaee, M., et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br. J. Dermatol. 162, 669-673 (2010).
40. Goreshi, R. et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J. Invest. Dermatol. 132, 1117-1124 (2012).
41. Huard, C. et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br. J. Dermatol. 176, 1224-1230 (2017).
42. Werth, V. P. et al. A phase 2 study of safety and efficacy o anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis [abstract]. Arthritis Rheum. 69 (Suppl.), 7L (2017).
43. Engel, A. G. &Arahata, K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann. Neurol. 16, 209-215 (1984).
44. Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343-356 (1990).
45. Griggs, R. C., et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705-713 (1995).
46. Van der Meulen, M. F. et al. Polymyositis: an overdiagnosed entity. Neurology 12, 316-321 (2003).
47. Brady, S., Squier, W. & Hilton-Jones, D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J. Neurol. Neurosurg. Psychiatr. 84, 1240-1246 (2013).
48. Rose, M. R. & ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044-1055 (2013).
49. Lloyd, T. E. et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 29, 426-433 (2014).
50. Stenzel, W., Goebel, H. H. & Aronica, E. Review: immunemediated necrotizing myopathies-a heterogeneous group of diseases with specific myopathological features. Appl. Neurobiol. Neuropathol. 38, 632-646 (2012).
51. Allenbach, Y. et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul. Disord. 28, 87-99 (2018).
52. Van de Vlekkert, J., Hoogendijk, J. E. & de Visser, M. Long-term follow-up of 62 patients with myositis. J. Neurol. 261, 992-998 (2014).
53. Pinal-Fernandez, I., Casciola-Rosen, L. A., Christopher-Stine, L., Corse, A. M. & Mammen, A. L. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J. Rheumatol. 42, 1448-1454 (2015).
54. Allenbach, Y., Benveniste, O., Goebel, H.-H. & Stenzel, W. Integrated classification of inflammatory myopathies. Neuropathol. Appl. Neurobiol. 43, 62-81 (2017).
55. Noguchi, E. et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 74, 992-999 (2017).
56. Mozaffar, T. & Pestronk, A. Myopathy with anti-Jo-1 antibodies: Pathology in perimysium and neighbouring muscle fibres. J. Neurol. Neurosurg. Psychiatry, 68, 472-478 (2000).
57. Aouizerate, J. et al. Myofiber HLA-DR espression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol. Commun. 23, 154 (2014).
58. Mescam-Mancini, L. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138, 2485-2492 (2015).
59. Stenzel, W. et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84, 1346-1354 (2015).
60. Uruha, A., Suzuki, S., Suzuki, N. & Nishino, I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain 139, e50 (2016).
61. Pinal-Fernandez, I. & Mammen, A. L. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr. Opin. Rheumatol. 28, 619-624 (2016).
62. De Visser, M., Emslie-Smith, A. M. & Engel, A. G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J. Neurol. Sci. 94, 181-192 (1989).
63. Wedderburn, L. R. et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 57, 1192-1201 (2007).
64. Patel, B. Neelam, K. & Werth, V. P. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J. Am. Acad. Dermatol. https://doi.org/10.1016/j. jaad.2017.12.055 (2017).
65. Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487-1498 (1991).
66. Pestronk, A. Acquired immune and inflammatory myopathies: pathologic classification. Curr. Opin. Rheumatol. 23, 595-604 (2011).